These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 22647432

  • 1. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
    Morishima Y, Honda Y, Kamisato C, Tsuji N, Kita A, Edo N, Shibano T.
    Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
    [Abstract] [Full Text] [Related]

  • 2. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y, Honda Y, Kamisato C, Shibano T.
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [Abstract] [Full Text] [Related]

  • 3. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y, Kamisato C, Honda Y.
    Eur J Pharmacol; 2014 Nov 05; 742():15-21. PubMed ID: 25179572
    [Abstract] [Full Text] [Related]

  • 4. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
    Fukuda T, Tsuji N, Honda Y, Kamisato C, Morishima Y, Shibano T.
    Thromb Haemost; 2011 Dec 05; 106(6):1062-8. PubMed ID: 21946952
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
    Fukuda T, Kamisato C, Honda Y, Matsushita T, Kojima T, Furugohri T, Morishima Y, Shibano T.
    Thromb Res; 2013 Jun 05; 131(6):540-6. PubMed ID: 23673387
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats.
    Morishima Y, Kamisato C, Honda Y, Furugohri T, Shibano T.
    Thromb Res; 2013 Jan 05; 131(1):59-63. PubMed ID: 22999414
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
    Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S.
    J Arthroplasty; 2014 Dec 05; 29(12):2439-46. PubMed ID: 25047458
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH, Al-Saady N, Jin J, Sun M, Melino M, Winters SM, Zamoryakhin D, Goette A.
    Am J Cardiol; 2017 Sep 01; 120(5):792-796. PubMed ID: 28709650
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.
    Am Heart J; 2010 Oct 01; 160(4):635-41. PubMed ID: 20934556
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
    Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Kiuchi Y, Abe K, Tachibana S.
    Thromb Res; 2014 Jun 01; 133(6):1016-22. PubMed ID: 24680549
    [Abstract] [Full Text] [Related]

  • 19. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U, Ku P, Malinowski J, Zhu BY, Scarborough RM, Marlowe CK, Wong PW, Lin PH, Hollenbach SJ.
    Eur J Pharmacol; 2000 Apr 21; 395(1):51-9. PubMed ID: 10781674
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.